Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is an excellent read on SGMO
https://t.co/XXLJtZOpQI
Looks like it's doing exactly what I predicted. I'll be adding more if it dips below $15.
loved how everyone was hatting this company at $9.00 2 month later its 20 so much cash and partnerships 30.00 target next year loaded up for more upside on SGMO & HGEN favorite two gene editing stocks both in phase 3
SGMO
https://www.businesswire.com/news/home/20201207005251/en/Pfizer-and-Sangamo-Announce-Updated-Phase-12-Results-Showing-Sustained-Factor-VIII-Activity-Levels-in-3x1013-VGKG-Cohort-Through-One-Year-Following-Hemophilia-A-Gene-Therapy
Humanigen Secures Exclusive Worldwide License to Gene-Editing Technology from Mayo Clinic to Improve CAR-T
Expands Humanigen’s intellectual property portfolio to include gene-edited CAR-T cells
Builds and further strengthens Humanigen’s leadership position in GM-CSF neutralization
$SGMO
SGMO owns patents on CRSPR technology used by CRSP - SGMO will file lawsuits when real value (revenues) are ready to be generated.
SGMO moving here now
HC Wainright tags SGMO at 25.00. My guess it 2-4 months it pops towards 25-30..
No, I think it plays catchup to the sector. $EDIT $CRSP $NTLA are too hot...
I think later next year if we see positive results coming in from the studies the stock will move much higher. In the meantime we could be range bound between 14-20. I'm not so sure we're a take over candidate with all the collaborations we have. It's really a poison pill. It sure would be a very complex buyout.
SGMO Sangamo has prioritized intellectual property as an essential component of their business. They have a dominant proprietary patent estate for zinc fingers design and methods. They also own more CRISPR patents than CRISRP (CRSP), Editas (EDIT) and Intellia (NTLA) combined. The 2019 CRISPR 10k states they own approximately 25 granted patents worldwide, relying primarily on in-licensing which is clouded by ongoing patent litigation. https://seekingalpha.com/article/4395956-sangamo-good-companies-get-bought-not-sold
Got some Jan $20 calls
$SGMO$
A double from here looks very doable comparing market caps to $CRSP $EDIT $NTLA
SGMO moving toward stratosphere, finally...50-100.
$SGMO added some calls, I think Sangamo is going to play catchup to $CRSP $EDIT and the whole gang...
$20.00 soon hasn't run like Beam or Edit we will have our day in the sun.
$SGMO
Strong close yesterday. Someone acquiring 100k, 200k towards close
What happened to the hiv drug they had years ago.
Sangamo participates in a conference call with Truist Conference call with management will be held on December 11 at 12 pm hosted by Truist
Read more at:
https://thefly.com/n.php?id=3207168
I loaded next weeks. The $15’s I bought at .35 today closed over $2.
I’m hoping for continuation into tomorrow to sell into. 10X your money is too hard to pass up if I can get it!
Nice! There are lotto calls which are my crack and then there are longer term options which can be very profitable.
GL Brother!
May I ask you what time period you chose for your call options?
Thanks
LOL Ain't that the Truth my Friend! That's how it Rolls in options! :) Now I'm hoping my KODK January calls pay off for me! LOL I took a decent profit on my KODK December 18th calls on that last pop. Those went from .05 cents to over $1.50 for me. If they get the loan approval before then I will be in the Money on my new calls! Fingers Crossed!!!
God I hope it is a buyout, I literally bought every Call option I could. $15 $16 and $17 for next friday.
A buyout at $20-$25 would make my year lol!
DT it got to $13 lol! Just took a little longer than expected...
I bought an ass load more of Calls here! $SGMO
Finally is right. I am glad I was patient. Could we see $20s soon? We get bought by Pfizer?
I agree! I have options that are going to expire tomorrow, but I think this is a great long-term investment. I was really hoping for some sort of Big rally by the end of the week, but that seems to be fading for my calls. I still like this company though. Lots of potential here.
Took at starter almost a billion in cash I'm in heavy.
Great Partnerships.
$SGMO
Come on SGMO Move up to around $13 for me and I will be very happy!
I wonder why SGMO has gone down so much in the last two trading sessions? The open interest is still insane on the July $13 calls. I got my fingers crossed here as I got some $12 calls for July!
PFE is a partner with SGMO in Hemo. PFE CEO telegraphed to participants at a Goldman Sachs conf earlier this week that favorable or positive data was forthcoming. SGMO had announced they would be releasing data on the 18th....so you can be the judge. Huge call buying in July 13's
jim pappa
@jim_pappa
Replying to
@MWM76
and
@fezziwig2019
Followers
|
86
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
797
|
Created
|
09/09/04
|
Type
|
Free
|
Moderators |
http://www.sangamo.com/index.php
http://finance.yahoo.com/q/ks?s=SGMO+Key+Statistics
Sangamo Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on translating ground-breaking science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company?s proprietary zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation. The ZFPs could be engineered to make ZFP nucleases (ZFNs), proteins that could be used to specifically modify DNA sequences by adding or knocking out specific genes; and ZFP transcription factors (ZFP TFs), proteins that can be used to turn genes on or off. Its therapeutic products include SB-728-T, a ZFN-mediated autologous T-cell product for human immunodeficiency virus and acquired immunodeficiency syndrome (HIV/AIDS), which is in Phase II and Phase I clinical trials; and SB-728-HSPC that is in Phase I/II clinical trials for HIV/AIDS. The company also engages in Phase I/II studies of in vivo genome editing applications of ZFP Therapeutics for hemophilia B, Hemophilia A, and Mucopolysaccharidosis I (MPS) and MPS II, which are lysosomal storage disorder (LSD); proprietary preclinical programs in other LSDs; and research stage programs in certain central nervous system disorders and cancer immunotherapies. It has collaborative partnerships with Biogen Inc. to develop therapeutic genome editing products in hemoglobinopathies; and with Shire International GmbH to develop the preclinical development program in Huntington?s disease, as well as license agreement with Sigma-Aldrich Corporation to develop ZFP-based laboratory research reagents and Dow AgroSciences, LLC to modify the genomes or alter protein expression of plant cells, plants, or plant cell cultures. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Richmond, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |